{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/vestibular-neuronitis/prescribing-information/cyclizine/","result":{"pageContext":{"chapter":{"id":"354fa7f8-799b-53ab-900a-b4083df52ec8","slug":"cyclizine","fullItemName":"Cyclizine","depth":2,"htmlHeader":"<!-- begin field 2048f6b1-1e6c-4a49-840e-a82c00a46372 --><h2>Cyclizine</h2><!-- end field 2048f6b1-1e6c-4a49-840e-a82c00a46372 -->","summary":"","htmlStringContent":"<!-- begin item 0fa62089-16bd-4b7f-b792-a82c00a4619e --><!-- end item 0fa62089-16bd-4b7f-b792-a82c00a4619e -->","topic":{"id":"4161326f-3a9d-549b-a377-dc2f2a6f809a","topicId":"d53e1081-ae57-4dcc-8ee8-14e6be6fb3d6","topicName":"Vestibular neuronitis","slug":"vestibular-neuronitis","lastRevised":"Last revised in November 2017","chapters":[{"id":"1371e2f5-4cd3-5674-aae3-79470e21b62b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"cb3f7155-69a7-5a7f-b8c1-2a1a113f0070","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a45dcd81-fea0-598a-ba01-782b350ffabd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"06a83e39-ba88-5cb5-872a-7b5e56e06a3c","slug":"changes","fullItemName":"Changes"},{"id":"c9683178-6f5b-5445-a2d4-02d27c379f4b","slug":"update","fullItemName":"Update"}]},{"id":"a9baddc3-bb87-54e7-b6bf-fb890ce8d86d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"65c0b807-ad55-5cb6-8ac0-1beaf353fd29","slug":"goals","fullItemName":"Goals"},{"id":"c577b7a6-4f03-5974-a443-32000f43d67c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"300cd325-7e03-5d62-afb6-803945166705","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4e3892d6-0403-52e9-a509-fc65bd12340b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c67ef3c1-dad6-5fbc-9fc2-1f9ef2f8fcef","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e83fe4f4-878e-59eb-a20b-f35218ed5023","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d4fd633a-c05b-5b41-9dc2-d862bc4286b5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8ab4ebcd-03e4-5892-9e29-aabb20cb8f45","slug":"definition","fullItemName":"Definition"},{"id":"552f3d90-3666-593b-b806-28115dcd8f3b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1966c14e-e128-5b21-bbce-6b9d4f48924d","slug":"complications","fullItemName":"Complications"},{"id":"f30ad763-2643-586e-9d19-cffd5f45d021","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"adbff71b-d255-5959-953d-3b2788094c8b","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"081f5ce9-172b-5beb-9ace-bbe7a9e86705","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ba7e323e-e894-5821-9164-ea7cd07a38b4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7c05a5c3-6c86-5daa-aed5-df8280f3723a","fullItemName":"Management","slug":"management","subChapters":[{"id":"f6abc1bb-cef0-5ec3-abe6-ca99c3f79fa7","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ac81d77a-e9b5-5b14-9a42-63c17716a3f4","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"1ae90a52-6113-534c-8cf7-46d78bb039a3","slug":"cinnarizine","fullItemName":"Cinnarizine"},{"id":"354fa7f8-799b-53ab-900a-b4083df52ec8","slug":"cyclizine","fullItemName":"Cyclizine"},{"id":"4df87a4b-4d5c-56b0-b766-c143a60b38e8","slug":"prochlorperazine","fullItemName":"Prochlorperazine"},{"id":"ac9da5a7-a091-516f-a6b1-03ed2d2f7156","slug":"promethazine-teoclate","fullItemName":"Promethazine teoclate"}]},{"id":"9f00019c-78be-54da-b9cb-69c6c04c5063","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c39d54c3-45ec-52b9-9dd2-efc3f3caa200","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d04e0140-1610-5826-9319-63f03c35c2d1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"763af5f7-891e-5c76-9970-ae093e35ae7b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d0088dd9-7199-53a5-a4d0-e4299a54c061","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c9ae115f-4e3a-5af0-870e-16c967836515","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"27450791-3a41-5a8d-951b-efe744ca7944","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"49115179-8551-5f4b-9d71-06a60c3445da","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ac81d77a-e9b5-5b14-9a42-63c17716a3f4","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"0536f765-58fb-5f83-80c6-45baa5bf3c5c","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 7e3c1cd4-997a-4ace-80f5-a82c00a48a98 --><h3>What dosage of cyclizine should I prescribe?</h3><!-- end field 7e3c1cd4-997a-4ace-80f5-a82c00a48a98 -->","summary":"","htmlStringContent":"<!-- begin item 1e9416bc-93a6-403b-9cd3-a82c00a488e4 --><!-- begin field f0111ec2-537a-423c-a57f-a82c00a48a98 --><ul><li>For nausea, vomiting, vertigo, or labyrinthine disorders, prescribe cyclizine 50 mg orally up to three times a day [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">BNF 74, 2017</a>].</li><li>If the oral route is not appropriate, cyclizine 50 mg by intramuscular injection can be given up to three times a day [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">ABPI Medicines Compendium, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">BNF 74, 2017</a>].</li></ul><!-- end field f0111ec2-537a-423c-a57f-a82c00a48a98 --><!-- end item 1e9416bc-93a6-403b-9cd3-a82c00a488e4 -->","subChapters":[]},{"id":"49ee9558-7c7b-5e91-81ad-2057f39d6b41","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field e67a754f-fa73-48d0-be93-a82c00a4a6ff --><h3>What are the contraindications and cautions when prescribing cyclizine?</h3><!-- end field e67a754f-fa73-48d0-be93-a82c00a4a6ff -->","summary":"","htmlStringContent":"<!-- begin item 5e09331c-e09f-4eba-b59f-a82c00a4a576 --><!-- begin field c50a5bf2-6663-486f-a39b-a82c00a4a6ff --><ul><li><strong>Do not prescribe cyclizine to people with:</strong><ul><li>Hypersensitivity to cyclizine or its excipients.</li><li>Severe liver disease — increased risk of coma.</li><li>Porphyria.</li></ul></li><li><strong>Prescribe cyclizine with caution to people with:</strong><ul><li>Prostatic hypertrophy, urinary retention, susceptibility to angle-closure glaucoma, and pyloroduodenal obstruction.</li><li>Hepatic disease.</li><li>Epilepsy.</li><li>Severe heart failure or acute myocardial infarction — cyclizine may cause a fall in cardiac output associated with increases in heart rate, mean arterial pressure, and pulmonary wedge pressure.</li><li>Phaeochromocytoma.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">BNF 74, 2017</a>] </p><!-- end field c50a5bf2-6663-486f-a39b-a82c00a4a6ff --><!-- end item 5e09331c-e09f-4eba-b59f-a82c00a4a576 -->","subChapters":[]},{"id":"90643b18-2485-550d-85cc-4baf12923be7","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 673ec39f-15e9-4203-9477-a82c00a4bfa0 --><h3>What are the adverse effects of cyclizine?</h3><!-- end field 673ec39f-15e9-4203-9477-a82c00a4bfa0 -->","summary":"","htmlStringContent":"<!-- begin item 2f1c1116-27cb-47ef-8646-a82c00a4bc19 --><!-- begin field 0e8fb800-56f9-4b63-937a-a82c00a4bfa0 --><ul><li><strong>Drowsiness</strong> is a significant adverse effect with most of the older antihistamines (such as cyclizine), especially with high doses or in the elderly.</li><li><strong>Other adverse effects include:</strong><ul><li>Psychiatric — restlessness, nervousness, euphoria, disorientation, insomnia, and auditory and visual hallucinations.</li><li>Neurological — headache, dystonia, dyskinesia, extrapyramidal motor disturbances, tremor, seizures, dizziness, somnolence and decreased consciousness, speech disorders (transient), paraesthesia, and generalized chorea.</li><li>Cardiovascular — tachycardia, palpitations, arrhythmias, hypertension, and hypotension.</li><li>Respiratory — bronchospasm and apnoea.</li><li>Gastrointestinal and hepatic — dry mouth, nose and throat; constipation; increased gastric reflux; nausea, vomiting, and diarrhoea; stomach pain; loss of appetite; hepatic dysfunction; cholestatic jaundice and hepatitis.</li><li>Skin — rashes, urticaria, angio-oedema, allergic skin reactions, and fixed drug eruption photosensitivity.</li><li>Musculoskeletal — twitching and muscle spasms.</li><li>Immune system — hypersensitivity reactions, including anaphylaxis.</li><li>Blood and lymphatic system — agranulocytosis, haemolytic anaemia, leucopenia, and thrombocytopenia.</li><li>Others — tinnitus, blurred vision and oculogyric crisis, and urinary retention.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">BNF 74, 2017</a>]</p><!-- end field 0e8fb800-56f9-4b63-937a-a82c00a4bfa0 --><!-- end item 2f1c1116-27cb-47ef-8646-a82c00a4bc19 -->","subChapters":[]},{"id":"ad3f9e06-547d-5c3b-927e-739d5fc15cd0","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 6bf6e47f-52ed-4934-9fd2-a82c00a4d74b --><h3>What drug interactions occur with cyclizine?</h3><!-- end field 6bf6e47f-52ed-4934-9fd2-a82c00a4d74b -->","summary":"","htmlStringContent":"<!-- begin item 2a813051-a8cf-4173-a2a4-a82c00a4d549 --><!-- begin field 25212783-57f9-4b0a-959f-a82c00a4d74b --><ul><li>Important drug interactions with cyclizine include:<ul><li>Alcohol — the anti-emetic effect of cyclizine may increase the toxic effects of alcohol.</li><li>Antimuscarinic drugs — there is a risk of increased antimuscarinic adverse effects when cyclizine is given with other antimuscarinic drugs. </li><li>Central nervous system (CNS) depressant drugs — cyclizine may have additive effects with other CNS depressants, such as opioid analgesics.</li><li>Ototoxic drugs — cyclizine may disguise signs indicating the onset of damage caused by ototoxic drugs (such as aminoglycoside antibiotics).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">BNF 74, 2017</a>]</p><!-- end field 25212783-57f9-4b0a-959f-a82c00a4d74b --><!-- end item 2a813051-a8cf-4173-a2a4-a82c00a4d549 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}